

Taiwan's Amaran Biotech signs MoU with Nippon to expand CDMO business

12 March 2025 | News

To inject significant momentum into CDMO business development in Japan, Taiwan, and the global market



Amaran Biotechnology Inc., a subsidiary of OBI Pharma specialising in Contract Development and Manufacturing Organization (CDMO) services for next-generation pharmaceuticals, has signed a Memorandum of Understanding (MoU) with Nippon Fine Chemical Co., Ltd., and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd.

The three parties aim to deepen collaboration in the field of nanoparticle-based drug CDMO manufacturing while expanding their presence in Taiwan, Japan, and international CDMO markets.

Amaran Biotech boasts Taiwan's first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals. Nippon Fine Chemical, a century-old Japanese company, specializes in phospholipids technology with over 40 years of R&D expertise. Its innovative Presome™ series products, used as drug carriers, enhance drug targeting and stability while reducing toxicity and enabling sustained release.

Through this partnership, Amaran Biotech will utilise its unique aseptic filling line and CDMO services to support Nippon Fine Chemical's production of nanoparticle-based drug, including liposomes and lipid nanoparticles (LNPs). The services provided will include sterile filtration, aseptic filling, packaging, storage, and quality management.

The collaboration extends to Zillion Fine Chemicals' CDMO operations in Taiwan, with the three parties working together to complement each other's strengths and upgrade the technology and services of the CDMO markets in Taiwan, Japan, and beyond.

Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, stated: "Amaran continues to follow its motto of "Work Locally. Think and Act Globally". Ryan Lo, Vice President of Corporate Strategy, Business Development & Regulatory Affairs highlighted that, "Amaran's industry-leading aseptic filling line and extensive experience in pharmaceutical production have earned Nippon Fine Chemical's trust. This collaboration not only provides a more comprehensive solution for nanoparticle-based drug CDMO but also aims to create synergistic business opportunities that multiply the value of our efforts." Masaki Matsumoto, Senior General Manager of Nippon Fine Chemical, commented: "The nanoparticle-based drug market holds tremendous growth potential. We believe this partnership will inject significant momentum into our CDMO business development in Japan, Taiwan, and the global market."